Capital International Sarl Raises Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Capital International Sarl boosted its holdings in BioNTech SE (NASDAQ:BNTX) by 1.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,058 shares of the company’s stock after purchasing an additional 310 shares during the period. Capital International Sarl’s holdings in BioNTech were worth $2,219,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Baillie Gifford & Co. boosted its holdings in BioNTech by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock valued at $917,056,000 after purchasing an additional 86,343 shares during the last quarter. Primecap Management Co. CA lifted its holdings in BioNTech by 2.8% during the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after buying an additional 131,490 shares during the last quarter. Harding Loevner LP bought a new position in BioNTech during the 4th quarter worth approximately $410,984,000. Flossbach Von Storch AG lifted its holdings in BioNTech by 1.0% during the 4th quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock worth $374,526,000 after buying an additional 35,445 shares during the last quarter. Finally, Capital World Investors lifted its holdings in BioNTech by 1.5% during the 4th quarter. Capital World Investors now owns 938,747 shares of the company’s stock worth $99,075,000 after buying an additional 14,027 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on BNTX. Evercore ISI began coverage on BioNTech in a report on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price on the stock. TD Cowen raised their price target on BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a report on Tuesday, May 7th. BMO Capital Markets cut their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a report on Tuesday, May 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $113.00 price target on shares of BioNTech in a report on Wednesday, June 26th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $111.70.

BioNTech Stock Performance

BNTX traded up $1.26 during trading hours on Friday, hitting $85.94. The company’s stock had a trading volume of 264,744 shares, compared to its average volume of 691,346. BioNTech SE has a fifty-two week low of $78.02 and a fifty-two week high of $125.83. The firm has a market capitalization of $20.43 billion, a PE ratio of 171.88 and a beta of 0.23. The company has a 50-day simple moving average of $89.32 and a 200 day simple moving average of $91.59. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, May 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.60). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The firm had revenue of $203.69 million for the quarter, compared to analyst estimates of $589.96 million. As a group, sell-side analysts expect that BioNTech SE will post -2 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.